Q4
Q4 Inc. (TSX:QFOR) (“Q4” or the “Company”), a leading capital markets communications platform, today announced its financial results for the three month period ended March 31, 2022. All amounts are expressed in US dollars unless otherwise stated.
“Our performance for the first quarter highlights the durability and agility of our business model,” said Darrell Heaps, CEO of Q4. “While top line and bottom line results were in line with our expectations, we were especially excited to see the record increase in customer expansion sales and controllable client retention. We believe this demonstrates our ability to provide our clients with a growing number of valuable solutions and services, and is directly correlated to our investments in our technology platform, as well as our focused effort of selling into our established customer base. Looking out to the second half of the year, we would expect material investments to tail off, and to realize greater leverage and accelerating revenue growth as we execute on our growth and path to profitability strategy.”
First Quarter 2022 Financial Highlights
- Delivered revenue of $13.9 million, an increase of 23.1% from the comparative period in the prior year
- Drove annual recurring revenue1 as of March 31, 2022 to $52.8 million, increasing 18.1% year over year
- Average recurring revenue per account (ARPA) grew 3.2% for the quarter, an increase of 12.2% over the preceding quarter's ARPA growth rate of 2.8%
- Expanded gross margin by 300 basis points year over year to 57.4%
- Net loss of $6.6 million, or $0.17 per share
- Adjusted EBITDA2 loss of $7.1 million
First Quarter and Subsequent to Quarter-End Operational Highlights
- Completed Q1 with 2,673 total customers (including customers in the Company’s backlog) compared to 2,391 customers from the prior year period
- Increased the number of products existing customers are using, driving growth in ARPA
- The migration of our corporate earnings webcasting platform continued on plan, with the company delivering 734 earnings events year to date, and over 1000 earnings events in total, since launching the platform
- Continued expansion of Capital Markets Events business to include hybrid and in-person capabilities in addition to fully virtual, resulting in the growth of Q4- hosted sell-side investor conferences and bus tours
- Launched Video Earnings product and expanded set of features to our Virtual Investor Day product
- Signed 3-year extension with New York Stock Exchange and their new expanded issuer services program, offering a broad list of virtual events that go beyond quarterly earnings calls, including but not limited to investor days, ESG events, corporate town halls, and partnering with the NYSE to host in-person events at the Exchange with the benefit of video broadcasting
- Announced Normal Course Issuer Bid on March 23rd to provide us with the flexibility to repurchase stock based on management’s ongoing assessments of the capital needs of the business, the market price of Q4’s common stock and general market conditions
Webcast Information
Q4 will host a webcast with Darrell Heaps, CEO, Ryan Levenberg, exiting CFO and Interim CFO Donna de Winter, to discuss the Company's financial results at 9:30 am ET on Wednesday, May 4, 2022. Participants can register in advance or access the webcast live at https://events.q4inc.com/attendee/251269858 . Supplemental materials will be available at least fifteen minutes prior to the start of the event. A replay of the webcast will be available at investors.q4inc.com shortly after the event concludes.
Audience questions will be taken real-time via the Q4 Platform. Investors can also submit their questions in advance to ir@q4inc.com or via our IR website . We will do our best to respond to your questions either on the webcast, if time permits or shortly thereafter. We appreciate your interest.
Q4's unaudited interim condensed consolidated financial statements and management's discussion and analysis for the three month period ended March 31, 2022 will be available on Q4's IR website and will be filed on SEDAR at www.sedar.com .
First Quarter 2022 Results
Selected Financial Measures
Revenue |
|
|
|
|
||||
|
Three Months Ended March 31, |
|||||||
|
2022 |
|
2021 |
|
Change |
|
Change |
|
(U.S. dollars in thousands) |
$ |
|
$ |
|
$ |
|
% |
|
Capital markets platform |
12,864 |
|
10,598 |
|
2,266 |
|
21.4% |
|
Platform services |
1,063 |
|
719 |
|
344 |
|
47.8% |
|
Other |
18 |
|
8 |
|
10 |
|
|
|
Total revenue |
13,945 |
|
11,325 |
|
2,620 |
|
23.1% |
|
Gross profit |
8,006 |
|
6,161 |
|
1,845 |
|
29.9% |
|
Percentage of total revenue |
57.4% |
|
54.4% |
|
|
|
|
|
Key Performance Indicators
|
March 31, 2022 |
March 31, 2021 |
Change |
Change |
||||||||
(U.S. dollars, except ARR which is in millions) |
$ |
$ |
$ |
% |
||||||||
Annual Recurring Revenue |
$ |
52.8 |
|
$ |
44.7 |
|
$ |
8.1 |
|
18.1 |
% |
|
Average Revenue per Account |
$ |
18,404 |
|
$ |
17,837 |
|
$ |
567 |
|
3.2 |
% |
|
Results of Operations
The following table outlines our consolidated statement of loss and comprehensive loss for the three months ended March 31, 2022 and 2021:
|
Three Months Ended |
|||
|
March 31, |
|||
|
2022 |
|
2021 |
|
(U.S. dollars in thousands) |
$ |
|
$ |
|
Revenue |
13,945 |
|
11,325 |
|
Direct cost of revenue |
5,939 |
|
5,164 |
|
Gross profit |
8,006 |
|
6,161 |
|
Operating Expenses |
|
|
|
|
Sales and marketing |
5,144 |
|
4,393 |
|
Research and development |
4,130 |
|
2,840 |
|
General and administrative |
5,771 |
|
4,983 |
|
Depreciation and amortization |
901 |
|
1,066 |
|
Foreign exchange gain |
(597) |
|
(27) |
|
Other expenses |
280 |
|
221 |
|
Total operating expenses |
15,629 |
|
13,476 |
|
Loss from operations |
(7,623) |
|
(7,315) |
|
Finance expenses |
21 |
|
131 |
|
Finance income |
(3) |
|
(1) |
|
(Gain) loss on derivative financial instruments |
(1,104) |
|
6,094 |
|
Loss before income taxes |
(6,537) |
|
(13,539) |
|
Income taxes |
60 |
|
(2) |
|
Net loss |
(6,597) |
|
(13,537) |
|
Other comprehensive loss |
|
|
|
|
Foreign exchange loss on foreign operations |
(11) |
|
(16) |
|
Net loss and comprehensive loss |
(6,608) |
|
(13,553) |
|
Basic and diluted loss per share |
(0.17) |
|
(1.46) |
|
Weighted average number of common shares outstanding - basic and diluted |
39,624 |
|
9,252 |
|
Key Balance Sheet Information
|
March 31, 2022 |
|
December 31, 2021 |
|
Change |
|
Change |
|
(U.S. dollars in thousands) |
$ |
|
$ |
|
$ |
|
% |
|
Cash |
55,827 |
|
63,283 |
|
$(7,456) |
|
(11.8)% |
|
Total assets |
101,848 |
|
109,117 |
|
(7,269) |
|
(6.7)% |
|
Total liabilities |
29,599 |
|
30,415 |
|
(816) |
|
(2.7)% |
|
Total long-term liabilities |
8,370 |
|
8,065 |
|
305 |
|
3.8% |
Non-IFRS Measures and Reconciliation of Non-IFRS Measures
This press release makes reference to certain non-IFRS financial measures including key performance indicators used by management and typically used by our competitors with software-as-a-service (“SaaS”) business models. These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore not necessarily comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS financial measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. These non-IFRS financial measures and industry metrics are used to provide investors with supplemental measures of our operating performance and liquidity and thus highlight trends in our business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS financial measures and industry metrics, in the evaluation of similar companies. Management also uses non-IFRS financial measures and industry metrics in order to facilitate operating performance comparisons from period to period, the preparation of annual operating budgets and forecasts and to determine components of executive compensation.
EBITDA and Adjusted EBITDA
We define EBITDA as net loss, adjusted for depreciation and amortization, finance expenses, finance income and income taxes. Adjusted EBITDA is a supplemental measure used by management to assess our financial and operating performance without regards to financing methods or capital structure. Adjusted EBITDA represents EBITDA, adjusted for the following: share-based compensation, unrealized foreign exchange (gain) loss, (gain) loss on derivative financial instruments, and transaction related expenses. We believe EBITDA and Adjusted EBITDA, two non-IFRS financial measures, are useful in assessing our operating cash flows as they eliminate the effects of non-cash expenses and one-time or non-recurring items recorded in the statements of loss and comprehensive loss. The Company’s definition of EBITDA and Adjusted EBITDA may be different than similarly titled measures used by other companies. The following table reconciles Adjusted EBITDA to net loss for the periods indicated.
|
Three Months Ended |
|||||
|
March 31, |
|||||
|
2022 |
|
2021 |
|||
(U.S. dollars in thousands) |
$ |
|
$ |
|||
Net loss |
(6,597 |
) |
(13,537 |
) |
||
Depreciation and amortization |
901 |
|
1,066 |
|
||
Finance expenses(1) |
21 |
|
131 |
|
||
Finance income |
(3 |
) |
(1 |
) |
||
Income taxes |
60 |
|
(2 |
) |
||
EBITDA |
(5,618 |
) |
(12,343 |
) |
||
Other adjustments |
|
|
||||
Share-based compensation expense(2) |
148 |
|
247 |
|
||
Unrealized foreign exchange (gain) loss(3) |
(597 |
) |
54 |
|
||
(Gain) loss on derivative financial instruments(4) |
(1,104 |
) |
6,094 |
|
||
Transaction related expenses(5) |
22 |
|
366 |
|
||
Adjusted EBITDA |
(7,149 |
) |
(5,582 |
) |
||
| _____________________ | ||
Note: |
||
(1) |
Finance expenses are primarily related to interest and accretion of financial liabilities. |
|
(2) |
Share-based compensation includes non-cash expenditures recognized in connection with the issuance of options under our Legacy Equity Incentive Plan to our employees and directors. Options granted under the Legacy Equity Incentive Plan have become options under our Omnibus Equity Incentive Plan (the “Omnibus Plan”) in connection with the IPO in 2021. This amount also includes the restricted share units ("RSUs") and performance share units ("PSUs") granted under the Omnibus Plan. |
|
(3) |
These adjustments represent the change in the value of foreign currency denominated transactions that are recorded in financial statements prior to the settlement of invoices. |
|
(4) |
These adjustments represent fair value adjustments relating to outstanding warrants. |
|
(5) |
Transaction related expense represents expenses relating to our IPO and include professional, legal, consulting and accounting fees that are non-recurring and would otherwise not have been incurred. |
|
Free Cash Flow
Free cash flow represents cash flow from (used in) operating activities less additions to property and equipment. We use Free cash flow, a non-IFRS financial measure, to assess the amount of cash available for dividend payments, debt repayment and other investing and financing activities. We believe that this information is useful to certain investors and analysts to evaluate the Company’s performance with respect to its operating cash flow capacity to meet non-discretionary outflows of cash. The following tables reconciles our cash flow from (used in) operating activities to Free cash flow:
|
Three Months Ended |
|||
|
March 31, |
|||
|
2022 |
|
2021 |
|
(U.S. dollars in thousands) |
$ |
|
$ |
|
Cash flow from (used in) operating activities |
(7,592) |
|
(4,416) |
|
Additions to property and equipment |
(279) |
|
(161) |
|
Free cash flow |
(7,871) |
|
(4,577) |
|
Key Performance Indicators
This press release also makes reference to “Annual Recurring Revenue” or “ARR” and “Average Revenue Per Account” or “ARPA”, which are key performance indicators we use to help us evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. Our key performance indicators may be calculated in a manner different from similar key performance indicators used by other companies. Definitions of these key performance indicators can be found under the heading “Key Performance Indicators” in the Company’s management’s discussion and analysis for the three months ended March 31, 2022 and 2021.
Forward-Looking Information
This press release may contain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, business operations, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. In certain cases, forward-looking statements that are predictive in nature, depend upon or refer to future events or conditions, and/or can be identified by the use of words such as “expect,” “continue,” “anticipate,” “intend,” “aim,” “plan,” “believe,” “budget,” “estimate,” “forecast,” “foresee,” “close to,” “target” or negative versions thereof and similar expressions, and/or state that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.
Forward-looking information is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Certain assumptions underlying the forward-looking information in this MD&A include: our ability to continue investing in infrastructure to support our growth and brand recognition; our ability to continue maintaining and enhancing our technological infrastructure and the functionality of our platform; our ability to develop and implement new product offerings; our ability to capitalize on growth opportunities and implement our growth strategy; our ability to build our market share and enter new geographies; the total addressable market for our products; our ability to retain key personnel; our ability to maintain existing customer relationships and to continue to expand our customers’ use of our platform and products; our ability to maintain existing relationships on similar terms with our current service providers, suppliers, channel partners and other third parties; our ability to maintain and expand our geographic scope; our ability to execute on our expansion plans; our ability to obtain financing on acceptable terms or at all; the impact of competition; the successful integration of future acquisitions; the changes and trends in our industry or the global economy; changes in laws, rules, regulations, and global standards; and that the risks and uncertainties noted below will not materialize.
Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that we considered appropriate and reasonable as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the following risk factors described in greater detail in the “Summary of Factors Affecting our Performance” and “Financial Instruments and Other Instruments” sections of this MD&A, and in the “Risk Factors” section of our Annual Information Form, which was filed on March 30, 2022, and is available under our profile on SEDAR at www.sedar.com .
If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. The opinions, estimates or assumptions referred to above are described in greater detail in "Summary of Factors Affecting our Performance" and should be considered carefully by prospective investors.
Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this MD&A represents our expectations as of the date of hereof (or as of the date they are otherwise stated to be made), and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
Additional information relating to Q4, can be found on SEDAR under the Company’s profile at www.sedar.com .
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,673 public companies globally including 50% of the S&P 500. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com .
_____________________
1
Annual recurring revenue or “ARR” is a key performance indicator. See “Key Performance Indicators”
2
Adjusted EBITDA is a non-IFRS measure. See “Non-IFRS Measures and Reconciliation of Non-IFRS Measures”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005282/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
